Lb Pharmaceuticals (LBRX) Income from Continuing Operations (2024 - 2026)
Lb Pharmaceuticals (LBRX) recorded quarterly Income from Continuing Operations of 19054000.0 in Q1 2026, down 66.09% quarter-over-quarter from 11472000.0 in Q4 2025, and down 259.1% on a YoY basis from 11975897.18 in Q1 2025.
Lb Pharmaceuticals (LBRX) Income from Continuing Operations (2024 - 2026) Analysis & Trends
Lb Pharmaceuticals' Income from Continuing Operations history runs 3 years deep, the most recent figure standing at 19054000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 259.1% year-over-year to 19054000.0; the TTM figure through Mar 2026 stood at 39388000.0 (changed N/A YoY), while the FY2025 annual figure was 25205000.0, up 60.06% from the prior year.
- Income from Continuing Operations was 19054000.0 for Q1 2026 at Lb Pharmaceuticals, down from 11472000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 3556000.0 in Q3 2025 to a low of 19054000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 9773333.33 across 3 years, with a median of 8389000.0 in 2025.
- The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations jumped 74.92% in 2025, then slumped 259.1% in 2026.
- A 3-year view of Income from Continuing Operations shows it stood at 5071000.0 in 2024, then plunged by 126.23% to 11472000.0 in 2025, then tumbled by 66.09% to 19054000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 19054000.0 (Q1 2026), 11472000.0 (Q4 2025), and 3556000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.40 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Lb Pharmaceuticals | 843.30 Mn | 843.30 Mn | - | -19.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.05 Mn |
| Dec 31, 2025 | -11.47 Mn |
| Sep 30, 2025 | -3.56 Mn |
| Mar 31, 2025 | -5.31 Mn |
| Dec 31, 2024 | -5.07 Mn |
| Sep 30, 2024 | -14.18 Mn |